These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35819713)

  • 1. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.
    Fournier CN
    Neurotherapeutics; 2022 Jul; 19(4):1180-1192. PubMed ID: 35819713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.
    Goyal NA; Berry JD; Windebank A; Staff NP; Maragakis NJ; van den Berg LH; Genge A; Miller R; Baloh RH; Kern R; Gothelf Y; Lebovits C; Cudkowicz M
    Muscle Nerve; 2020 Aug; 62(2):156-166. PubMed ID: 31899540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
    Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials.
    Rutkove SB; Zhang H; Schoenfeld DA; Raynor EM; Shefner JM; Cudkowicz ME; Chin AB; Aaron R; Shiffman CA
    Clin Neurophysiol; 2007 Nov; 118(11):2413-8. PubMed ID: 17897874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of biomarkers in clinical trials and future developments that will help identify novel biomarkers.
    Malaspina A
    Int Rev Neurobiol; 2024; 176():171-207. PubMed ID: 38802175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
    Diana A; Pillai R; Bongioanni P; O'Keeffe AG; Miller RG; Moore DH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006049. PubMed ID: 28067943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress, development, and challenges in amyotrophic lateral sclerosis clinical trials.
    Ashhurst JF; Tu S; Timmins HC; Kiernan MC
    Expert Rev Neurother; 2022; 22(11-12):905-913. PubMed ID: 36543326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M; Swash M
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering.
    Tang M; Gao C; Goutman SA; Kalinin A; Mukherjee B; Guan Y; Dinov ID
    Neuroinformatics; 2019 Jul; 17(3):407-421. PubMed ID: 30460455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.
    Karanevich AG; Statland JM; Gajewski BJ; He J
    BMC Med Res Methodol; 2018 Feb; 18(1):19. PubMed ID: 29409450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials.
    Witzel S; Frauhammer F; Steinacker P; Devos D; Pradat PF; Meininger V; Halbgebauer S; Oeckl P; Schuster J; Anders S; Dorst J; Otto M; Ludolph AC
    Transl Neurodegener; 2021 Aug; 10(1):31. PubMed ID: 34433481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
    Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M;
    Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in amyotrophic lateral sclerosis.
    McDermott CJ
    Curr Opin Neurol; 2019 Oct; 32(5):758-763. PubMed ID: 31335338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism.
    Mehta P; Raymond J; Han MK; Larson T; Berry JD; Paganoni S; Mitsumoto H; Bedlack RS; Horton DK
    J Med Internet Res; 2021 Dec; 23(12):e28021. PubMed ID: 34878988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.